Clinical Trials Directory

Trials / Unknown

UnknownNCT05558774

Long-term Outcomes After Percutaneous Closure of PFO

Long-term Echocardiographic and Clinical Outcomes After Percutaneous Closure of Patent Foramen Ovale

Status
Unknown
Phase
Study type
Observational
Enrollment
300 (estimated)
Sponsor
MC Medicor · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

International medical centre Medicor from Slovenia has reported 306 successful percutaneous closures of patent foramen ovale (PFO) from October 2006 till June 2022. The investigators are going to follow-up the participants clinically and with contrast transthoracic echocardiography (TTE) to define the percentage of functional percutaneous closure. The latter is defined with the number (ten or less) of contrast-bubbles in the left atrium during Valsalva maneuver and contrast (agitated saline) application. The clinical follow-up will show the recurrence of embolic events (cerebrovascular insults, transient ischemic attacks) after percutaneous closure. In addition all of the participants are going to be screened for atrial fibrillation. The patients with moderate residual shunts (more than ten bubbles in the left atrium) will then according to the protocol have a transesophageal echocardiogram (TEE) to show the eventual mechanism of the shunt. If the TEE will not show any signs of a residual shunt, the patients will undergo a computed tomography angiogram (CTA) of the pulmonary circulation to exclude arterio-venous fistulas as a cause of the shunt seen on TTE. The investigators will also show the comparison in functional closure between classic and alternative device occluders.

Conditions

Timeline

Start date
2022-07-11
Primary completion
2023-07-11
Completion
2024-07-11
First posted
2022-09-28
Last updated
2022-09-28

Locations

1 site across 1 country: Slovenia

Source: ClinicalTrials.gov record NCT05558774. Inclusion in this directory is not an endorsement.